Inactive Instrument

ExpreS2ion Biotech Holding AB Share Price Nasdaq Stockholm

Equities

SE0008348262

Pharmaceuticals

Financials

Sales 2024 * 8M 758K 58.37M Sales 2025 * 8M 758K 58.37M Capitalization 85.3M 8.08M 622M
Net income 2024 * -25M -2.37M -182M Net income 2025 * -37M -3.51M -270M EV / Sales 2024 * 3.78 x
Net cash position 2024 * 55.05M 5.22M 402M Net cash position 2025 * 14.16M 1.34M 103M EV / Sales 2025 * 8.89 x
P/E ratio 2024 *
-2.66 x
P/E ratio 2025 *
-1.82 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate CI
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial MT
ExpreS2ion Biotech Unit Secures EUR8 Million Grant for Virus Vaccine Project; Shares Soar MT
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ExpreS2ion Biotech Holding AB Announces Changes to Leadership Team CI
Expres2ion Biotech Affiliate to Assess Strategic Options for Breast Cancer Project MT
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Certain Shares of ExpreS2ion Biotech Holding AB are subject to a Lock-Up Agreement Ending on 14-JUL-2023. CI
ExpreS2ion Biotech Holding AB(OM:EXPRS2) dropped from S&P Global BMI Index CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
ExpreS2ion Biotech Holding AB Auditor Raises 'Going Concern' Doubt CI
ExpreS2ion Biotech to Issue New Units to Guarantors Under Rights Issue MT
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer - 31/12/15
Director of Finance/CFO 48 30/09/20
Chief Tech/Sci/R&D Officer - 31/12/12
Members of the board TitleAgeSince
Director/Board Member 56 31/03/17
Director/Board Member 67 25/05/21
Founder 64 31/12/09
More insiders
ExpreS2ion Biotech Holding AB is a Sweden-based biopharmaceutical company. The Company specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The Company's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. It also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
More about the company